EU approves Novo Nordisk's Wegovy for heart, stroke treatment

7,881 次觀看・3 個月前

Novo Nordisk's (NVO) weight-loss drug Wegovy received the approval of European Union (EU) regulators to use the GLP-1 to treat heart issues and reduce stroke risks.

Anjalee Khemlani explains the details of Novo Nordisk's data on this treatment method.

For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.

This post was written by Luke Carberry Mogan.